Efficacy of CAR T-cell therapy in large tumors relies upon stromal targeting by IFNγ

Cancer Research

Volumn 74, Issue 23, 2014, Pages 6796-6805

  Textor, Ana ^a   Listopad, Joanna J ^a   Wührmann, Lara Le ^a   Perez, Cynthia ^a   Kruschinski, Anna ^a   Chmielewski, Markus ^b   Abken, Hinrich ^b   Blankenstein, Thomas ^a,c   Charo, Jehad ^a,d  

^a MAX DELBRÜCK CENTER FOR MOLECULAR MEDICINE   (Germany)

^b UNIVERSITY OF COLOGNE   (Germany)

^c CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^d F HOFFMANN LA ROCHE LTD   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

CD28 ANTIGEN; CHIMERIC ANTIGEN RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; GAMMA INTERFERON; GAMMA INTERFERON RECEPTOR; MAJOR HISTOCOMPATIBILITY ANTIGEN; TUMOR ANTIGEN; ERBB2 PROTEIN, HUMAN; HYBRID PROTEIN; INTERFERON RECEPTOR; LYMPHOCYTE ANTIGEN RECEPTOR;

ADOPTIVE IMMUNOTHERAPY; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIGEN RECOGNITION; ANTIGEN SPECIFICITY; ARTICLE; CANCER CELL; CANCER IMMUNOTHERAPY; CELL ENGINEERING; CHIMERIC ANTIGEN RECEPTOR T CELL THERAPY; CROSS PRESENTATION; ERADICATION THERAPY; LYMPHOCYTE MIGRATION; LYMPHOCYTE PROLIFERATION; MACROPHAGE; MOUSE; NATURAL KILLER CELL; NONHUMAN; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; SOLID TUMOR; STROMA; STROMA CELL; T LYMPHOCYTE; TISSUE INJURY; TUMOR MODEL; TUMOR REJECTION; TUMOR VOLUME; ADOPTIVE TRANSFER; ANIMAL; BIOLOGICAL THERAPY; CELL DIFFERENTIATION; CELL PROLIFERATION; HUMAN; IMMUNOLOGY; METABOLISM; PROCEDURES; TUMOR CELL LINE;

ADOPTIVE TRANSFER; ANIMALS; ANTIGENS, CD28; ANTIGENS, NEOPLASM; CELL DIFFERENTIATION; CELL LINE, TUMOR; CELL PROLIFERATION; CELL- AND TISSUE-BASED THERAPY; HUMANS; IMMUNOTHERAPY, ADOPTIVE; INTERFERON-GAMMA; MACROPHAGES; MICE; RECEPTOR, ERBB-2; RECEPTORS, ANTIGEN, T-CELL; RECEPTORS, INTERFERON; RECOMBINANT FUSION PROTEINS; STROMAL CELLS; T-LYMPHOCYTES;

EID: 84917710713     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-14-0079     Document Type: Article

References (33)

1. Eshhar Z, Waks T, Gross G, Schindler DG. Specific activation and targeting of cytotoxic lymphocytes through chimeric single chains consisting of antibody-binding domains and the gamma or zeta subunits of the immunoglobulin and T-cell receptors. Proc Natl Acad Sci U S A 1993;90:720-4.
2. Kershaw MH, Westwood JA, Parker LL, Wang G, Eshhar Z, Mavroukakis SA, et al. A phase I study on adoptive immunotherapy using gene-modifi ed T cells for ovarian cancer. Clin Cancer Res 2006;12: 6106-15.
3. Carpenito C, Milone MC, Hassan R, Simonet JC, Lakhal M, Suhoski MM, et al. Control of large, established tumor xenografts with genetically retargeted human T cells containing CD28 and CD137 domains. Proc Natl Acad Sci U S A 2009;106:3360-5.
4. Kochenderfer JN, Wilson WH, Janik JE, Dudley ME, Stetler-Stevenson M, Feldman SA, et al. Eradication of B-lineage cells and regression of lymphoma in a patient treated with autologous T cells genetically engineered to recognize CD19. Blood 2010;116: 4099-102.
5. Porter DL, Levine BL, Kalos M, Bagg A, June CH. Chimeric antigen receptor-modified T cells in chronic lymphoid leukemia. N Engl J Med 2011;365:725-33.
6. Yu P, Rowley DA, Fu Y-X, Schreiber H. The role of stroma in immune recognition and destruction of well-established solid tumors. Curr Opin Immunol 2006;18:226-31.
7. Spiotto MT, Rowley DA, Schreiber H. Bystander elimination of antigen loss variants in established tumors. Nat Med 2004;10:294-8.
8. Zhang B, Karrison T, Rowley DA, Schreiber H. IFN-gamma- and TNFdependent bystander eradication of antigen-loss variants in established mouse cancers. J Clin Invest 2008;118:1398-404.
9. Charo J, Perez C, Buschow C, Jukica A, Czeh M, Blankenstein T. Visualizing the dynamic of adoptively transferred T cells during the rejection of large established tumors. Eur J Immunol 2011;41: 3187-97.
10. Anders K, Buschow C, Herrmann A, Milojkovic A, Loddenkemper C, Kammertoens T, et al. Oncogene-targeting T cells reject large tumors while oncogene inactivation selects escape variants in mouse models of cancer. Cancer Cell 2011;20:755-67.
11. Listopad JJ, Kammertoens T, Anders K, Silkenstedt B, Willimsky G, Schmidt K, et al. Fas expression by tumor stroma is required for cancer eradication. Proc Natl Acad Sci U S A 2013;110:2276-81.
12. Restifo NP, Marincola FM, Kawakami Y, Taubenberger J, Yannelli JR, Rosenberg SA. Loss of functional beta 2-microglobulin in metastatic melanomas from five patients receiving immunotherapy. J Natl Cancer Inst 1996;88:100-8.
13. Choudhury A, Charo J, Parapuram SK, Hunt RC, Hunt DM, Seliger B, et al. Small interfering RNA (siRNA) inhibits the expression of the Her2/ neu gene, upregulates HLA class I and induces apoptosis of Her2/neu positive tumor cell lines. Int J Cancer 2004;108:71-7.
14. Felsher DW. Tumor dormancy and oncogene addiction. APMIS 2008;116:629-37.
15. Morgan RA, Johnson LA, Davis JL, Zheng Z, Woolard KD, Reap EA, et al. Recognition of glioma stem cells by genetically modi fied T cells targeting EGFRvIII and development of adoptive cell therapy for glioma. Hum Gene Ther 2012;23:1043-53.
16. Schietinger A, Philip M, Yoshida BA, Azadi P, Liu H, Meredith SC, et al. A mutant chaperone converts a wild-type protein into a tumor-specific antigen. Science 2006;314:304-8.
17. Song D-G, Ye Q, Carpenito C, Poussin M, Wang L-P, Ji C, et al. In vivo persistence, tumor localization, and antitumor activity of CAR-engineered T cells is enhanced by costimulatory signaling through CD137 (4-1BB). Cancer Res 2011;71:4617-27.
18. Hemmi S, Merlin G, Aguet M. Functional characterization of a hybrid human-mouse interferon gamma receptor: evidence for species-specific interaction of the extracellular receptor domain with a putative signal transducer. Proc Natl Acad Sci U S A 1992;89:2737-41.
19. Chmielewski M, Hombach AA, Abken H. CD28 cosignalling does not affect the activation threshold in a chimeric antigen receptor-redirected T-cell attack. Gene Ther 2011;18:62-72.
20. Chmielewski M, Hombach A, Heuser C, Adams GP, Abken H. T cell activation by antibody-like immunoreceptors: increase in affinity of the single-chain fragment domain above threshold does not increase T cell activation against antigen-positive target cells but decreases selectivity. J Immunol 2004;173:7647-53.
21. Kruschinski A, Moosmann A, Poschke I, Norell H, Chmielewski M, Seliger B, et al. Engineering antigen-specific primary human NK cells against HER-2 positive carcinomas. Proc Natl Acad Sci U S A 2008; 105:17481-6.
22. Hombach A, Wieczarkowiecz A, Marquardt T, Heuser C, Usai L, Pohl C, et al. Tumor-specific T cell activation by recombinant immunoreceptors: CD3 zeta signaling and CD28 costimulation are simultaneously required for efficient IL-2 secretion and can be integrated into one combined CD28/CD3 zeta signaling receptor molecule. J Immunol 2001;167:6123-31.
23. Stephan MT, Moon JJ,UmSH, Bershteyn A, Irvine DJ. Therapeutic cell engineering with surface-conjugated synthetic nanoparticles. NatMed 2010;16:1035-41.
24. Engels B, Engelhard VH, Sidney J, Sette A, Binder DC, Liu RB, et al. Relapse or eradication of cancer is predicted by peptide-major histocompatibility complex affinity. Cancer Cell 2013;23:516-26.
25. Briesemeister D, Sommermeyer D, Loddenkemper C, Loew R, Uckert W, Blankenstein T, et al. Tumor rejection by local interferon gamma induction in established tumors is associated with blood vessel destruction and necrosis. Int J Cancer 2011;128:371-8.
26. Klug F, Prakash H, Huber PE, Seibel T, Bender N, Halama N, et al. Lowdose irradiation programs macrophage differentiation to an iNOS. Cancer Cell 2013;24:589-602.
27. Pinthus JH, Waks T, Malina V, Kaufman-Francis K, Harmelin A, Aizenberg I, et al. Adoptive immunotherapy of prostate cancer bone lesions using redirected effector lymphocytes. J Clin Invest 2004;114: 1774-81.
28. Anders K, Blankenstein T. Molecular pathways: comparing the effects of drugs and T cells to effectively target oncogenes. Clin Cancer Res 2013;19:320-6.
29. Dolan BP, Gibbs KD, Ostrand-Rosenberg S. Tumor-specific CD4+ T cells are activated by "cross-dressed" dendritic cells presenting pep-tide-MHC class II complexes acquired from cell-based cancer vaccines. J Immunol 2006;176:1447-55.
30. Schuler T, Blankenstein T. Cutting edge: CD8+ effector T cells reject tumors by direct antigen recognition but indirect action on host cells. J Immunol 2003;170:4427-31.
31. Blankenstein T. The role of tumor stroma in the interaction between tumor and immune system. Curr Opin Immunol 2005;17:180-6.
32. Pucci F, Pittet MJ. Molecular pathways: tumor-derived microvesicles and their interactions with immune cells in vivo. Clin Cancer Res 2013;19:2598-604.
33. Riddell SR, Jensen MC, June CH. Chimeric antigen receptor -modified T cells: clinical translation in stem cell transplantation and beyond. Biol Blood Marrow Transplant 2013;19:S2-5.